NBW Capital LLC bought a new position in Exelixis, Inc. (NASDAQ:EXEL) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund bought 65,133 shares of the biotechnology company’s stock, valued at approximately $1,980,000.
A number of other large investors have also modified their holdings of EXEL. American Century Companies Inc. raised its position in Exelixis by 426.4% in the 4th quarter. American Century Companies Inc. now owns 1,469,945 shares of the biotechnology company’s stock worth $44,686,000 after buying an additional 1,190,691 shares during the last quarter. Jennison Associates LLC increased its position in shares of Exelixis by 38.1% during the 4th quarter. Jennison Associates LLC now owns 4,228,761 shares of the biotechnology company’s stock valued at $128,554,000 after purchasing an additional 1,167,758 shares during the last quarter. Macquarie Group Ltd. increased its position in shares of Exelixis by 811.5% during the 3rd quarter. Macquarie Group Ltd. now owns 1,276,453 shares of the biotechnology company’s stock valued at $30,928,000 after purchasing an additional 1,136,409 shares during the last quarter. Smith Asset Management Group LP purchased a new stake in shares of Exelixis during the 4th quarter valued at about $26,323,000. Finally, Wells Fargo & Company MN increased its position in shares of Exelixis by 36.5% during the 3rd quarter. Wells Fargo & Company MN now owns 3,042,694 shares of the biotechnology company’s stock valued at $73,723,000 after purchasing an additional 814,177 shares during the last quarter. 80.55% of the stock is owned by institutional investors and hedge funds.
In related news, Director Vincent T. Marchesi sold 15,000 shares of the stock in a transaction that occurred on Tuesday, March 6th. The shares were sold at an average price of $24.73, for a total value of $370,950.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Patrick J. Haley sold 45,029 shares of the stock in a transaction that occurred on Wednesday, February 28th. The stock was sold at an average price of $27.13, for a total transaction of $1,221,636.77. The disclosure for this sale can be found here. Insiders sold a total of 120,029 shares of company stock valued at $3,158,287 over the last three months. 5.10% of the stock is currently owned by insiders.
Exelixis (NASDAQ:EXEL) last released its earnings results on Monday, February 26th. The biotechnology company reported $0.12 earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.12. The company had revenue of $120.10 million during the quarter, compared to analyst estimates of $120.25 million. Exelixis had a net margin of 34.08% and a return on equity of 81.05%. The firm’s quarterly revenue was up 54.8% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.12 EPS. analysts anticipate that Exelixis, Inc. will post 0.59 EPS for the current year.
EXEL has been the subject of several research reports. Cann raised shares of Exelixis from a “market perform” rating to an “outperform” rating and set a $40.00 price target for the company in a research report on Tuesday, February 27th. They noted that the move was a valuation call. Stifel Nicolaus upped their price target on shares of Exelixis from $29.00 to $30.00 and gave the company a “hold” rating in a research report on Tuesday, February 27th. Zacks Investment Research raised shares of Exelixis from a “hold” rating to a “strong-buy” rating and set a $35.00 price target for the company in a research report on Tuesday, January 2nd. William Blair reaffirmed an “outperform” rating on shares of Exelixis in a research report on Monday, February 12th. Finally, BidaskClub raised shares of Exelixis from a “hold” rating to a “buy” rating in a research report on Thursday, January 25th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the stock. Exelixis has a consensus rating of “Buy” and a consensus target price of $34.10.
TRADEMARK VIOLATION WARNING: “NBW Capital LLC Takes Position in Exelixis, Inc. (EXEL)” was reported by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this article on another domain, it was stolen and reposted in violation of United States and international trademark & copyright laws. The correct version of this article can be read at https://sportsperspectives.com/2018/03/12/nbw-capital-llc-takes-position-in-exelixis-inc-exel.html.
Exelixis, Inc is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company’s cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors.
Want to see what other hedge funds are holding EXEL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Exelixis, Inc. (NASDAQ:EXEL).
Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.